Mental Health

In memory of her daughter Elora, a mother's foundation joins a global research network, turning personal tragedy into a collaborative fight against a rare cancer.

Bill C-34 aims to shield kids from online harms, but health advocates see a bigger prize: curbing the digital marketing of unhealthy products.

The Chinese Canadian Museum's new 'Momentum' exhibition uses sports to explore power, identity, and the overlooked stories of legendary athletes.

Paradisus La Perla's new WITT certification isn't just an award; it's a strategic move by Meliá to capture the booming $1.3T wellness travel market.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

As AI reshapes childhood with risks of addiction and anxiety, advocates argue that the oldest classroom—nature—is the most vital tool for building resilience.

One year in, the Facial Pain Registry has gathered data from 740 patients, creating an unprecedented resource to fight one of medicine's most misunderstood conditions.

A new app, born from its founder's personal health battle, challenges the 'no pain, no gain' ethos of digital wellness with a flexible, empathetic model.

Replacing a controversial task force, Canada's new NACPHS aims to modernize health guidelines with a focus on equity, patient input, and scientific agility.

An insurer's multi-million-dollar investment in anxiety care, featuring animal therapy, signals a shift in corporate responsibility. But what does it mean?

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

As illicit tobacco and vapes flood India, Big Tobacco calls for a crackdown. But is this a genuine partnership or a strategic play in a global shadow economy?

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

Arlow's new platform moves beyond reactive crisis management, using a hybrid AI and human-led system to proactively manage the entire aging journey.

Ottawa unveils the Safe Social Media Act, proposing an under-16 ban and a new regulator. Will this bold move save kids or stifle innovation?